; THE ADVANCEMENTS IN TREATMENT OF HIV-INFECTED PATIENTS WITH HERPETIC INFECTION.

Abstract

It was found on the base on the study of clinical and immunological parameters of 47 patients with HIV-associated herpes infections (recurrent labial herpes and/or aphthous stomatitis, genital herpes and shingles) that supplement of the basic therapy (valaciclovir 1.0 g daily intake orally 2 times a day for 7-10 days) 6 subcutaneous injections of the drug "Allokin-alpha" in dose 1 mg in a day enables significantly shorten the duration of clinical manifestations of herpes infections, reduce the frequency of relapses and also the duration of the first relapse after treatment. The immunoregulatory effect alokin-alpha used in the treatment of patients with HIV co-infection herpes is installed. Thus, the combination therapy provided a further reduce of CD4+-lymphocytes number at II clinical stage of HIV infection. The concentration of interleukin-8 (IL-8) decreased at I and II stages of immunodeficiency, that statistically weighty different from the values before treatment (P<0,05-0,02). Similarly, the level of IL-10 (P<0.05) decreased. It is important that the impact of treatment on immune parameters match the clinical effect.

• Authors: M Sokolenko, L Sokolenko, H Honchar, A Sokolenko, M Andrushchak
• Journal: Georgian medical news (Georgian Med News) 2020 Jul-Aug Issue 304-305 Pg. 56-61 ISSN: 1512-0112 [Print] Georgia (Republic)
• PMID: 32965250 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Valine
• Valacyclovir
• Acyclovir

Topics

• Acyclovir (therapeutic use)
• Antiviral Agents (therapeutic use)
• HIV Infections (complications, drug therapy)
• Humans
• Valacyclovir
• Valine